Search research articles
Contact Us
Filters
Showing results (31-40 of 62) with videos related to
Page
of 7
Sort By:
Leukemia & Lymphoma
|
September 18, 2015
Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience
Vijaya R Bhatt, Fausto R Loberiza, Lynette M Smith, et al.
British Journal of Haematology
|
February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months
Matthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.
American Journal of Clinical Oncology
|
November 7, 2013
Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy
Matthew A Lunning, Shelby Kutty, Eric T Rome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
Dan Douer, Ibrahim Aldoss, Matthew A Lunning, et al.
Haematologica
|
March 28, 2024
MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications
Chengfeng Bi, Yuhua Huang, Roshia Ali, et al.
Leukemia & Lymphoma
|
March 26, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas
Mwanasha H Merrill, Robert A Redd, David C Fisher, et al.
British Journal of Haematology
|
May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma
Robert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Blood Advances
|
July 5, 2022
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Juan P Alderuccio, Weiyun Z Ai, John Radford, et al.
The Lancet. Haematology
|
February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Blood
|
June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL
Jeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 62) with videos related to
Sort By:
Page
of 7
Leukemia & Lymphoma
|
September 18, 2015
Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience
Vijaya R Bhatt, Fausto R Loberiza, Lynette M Smith, et al.
British Journal of Haematology
|
February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months
Matthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.
American Journal of Clinical Oncology
|
November 7, 2013
Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy
Matthew A Lunning, Shelby Kutty, Eric T Rome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia
Dan Douer, Ibrahim Aldoss, Matthew A Lunning, et al.
Haematologica
|
March 28, 2024
MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications
Chengfeng Bi, Yuhua Huang, Roshia Ali, et al.
Leukemia & Lymphoma
|
March 26, 2025
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas
Mwanasha H Merrill, Robert A Redd, David C Fisher, et al.
British Journal of Haematology
|
May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma
Robert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Blood Advances
|
July 5, 2022
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Juan P Alderuccio, Weiyun Z Ai, John Radford, et al.
The Lancet. Haematology
|
February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Blood
|
June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL
Jeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.
Page
of 7